Third Harmonic Bio, Inc. ( THRD ) NASDAQ Global Market

Cena: 5.41 ( -0.18% )

Aktualizacja 07-25 22:00
NASDAQ Global Market
Branża: Biotechnology

Notowania:


Opis firmy:

Trzeci Harmonic Bio, Inc., firma biofarmaceutyczna na stadium klinicznym, koncentruje się na rozwoju leku w leczeniu chorób alergicznych i zapalnych. Opracowuje THB001, doustny inhibitor zestawu na małe cząsteczki do leczenia przewlekłej pokrzywki, choroby skórnej napędzanej aktywacją komórek tucznych, która powoduje wskazania czerwone, swędzące, bolesne lub ule, a także do wskazań dróg oddechowych i przewodu pokarmowego. Firma była wcześniej znana jako Project Ige, Inc. i zmieniła nazwę na Trzecie Harmonic Bio, Inc. w czerwcu 2019 r. Trzeci Harmonic Bio, Inc. został założony w 2019 roku i ma siedzibę w Cambridge, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 51
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 38.089
Ilość akcji: Brak danych
Debiut giełdowy: 2022-09-14
WWW: https://www.thirdharmonicbio.com
CEO: Ms. Natalie C. Holles
Adres: 300 Technology Square
Siedziba: 02139 Cambridge
ISIN: US88427A1079
Wskaźniki finansowe
Kapitalizacja (USD) 244 141 376
Aktywa: 304 493 000
Cena: 5.41
Wskaźnik Altman Z-Score: 32.8
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -4.4
Ilość akcji w obrocie: 38%
Średni wolumen: 261 529
Ilość akcji 45 127 796
Wskaźniki finansowe
Przychody TTM 836 000
Zobowiązania: 9 639 000
Przedział 52 tyg.: 3.18 - 16.02
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -1.2
P/E branży: 26.9
Beta: 2.861
Raport okresowy: 2025-08-06
WWW: https://www.thirdharmonicbio.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Natalie C. Holles Chief Executive Officer & Director 942 400 1973
Dr. Edward R. Conner M.D. Chief Medical Officer 672 000 1973
Ms. Julie Person Chief Administrative Officer 574 000 1974
Mr. Christopher Murphy Chief Financial & Business Officer 0 1984
Mr. Dennis Dean Ph.D. Chief Non-Clinical Development Officer 0 0
Ommer Chohan Treasurer & Secretary 0 0
Mr. Steven P. Sweeney Senior Vice President of Development Operations 0 0
Ms. Jennifer Dittman Chief Development Operations Officer 0 0
Dr. Christopher J. Dinsmore Ph.D. Chief Scientific Officer 0 1967
Lista ETF z ekspozycją na akcje Third Harmonic Bio, Inc.
Symbol ETF Ilość akcji Wartość
IWM 642 075 3 486 467
IWN 222 828 1 209 956
IBB 138 462 751 848
VTWO 109 485 570 416
SCHA 98 512 534 920
IWC 55 993 304 041
AVSC 33 416 181 448
BTEC.L 25 151 136 569
2B70.DE 25 151 136 569
BTEE.L 25 151 136 569
BTEK.L 25 151 136 569
DFAS 16 060 87 205
VTWV 13 859 72 205
RSSL 13 142 71 623
SCHB 12 349 67 055
IWV 10 559 57 335
XSU.TO 4 550 33 717
DFUS 2 783 15 111
UWM 2 542 13 803
DFAU 2 139 11 614
URTY 2 110 11 457
IBBQ 1 858 10 088
VTHR 1 689 8 799
BIB 1 662 9 024
DFAT 639 3 469
HDG 32 173
Wiadomości dla Third Harmonic Bio, Inc.
Tytuł Treść Źródło Aktualizacja Link
Third Harmonic Bio Announces Plan of Liquidation and Dissolution Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 globenewswire.com 2025-04-14 10:45:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) globenewswire.com 2025-03-27 10:10:00 Czytaj oryginał (ang.)
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-03-04 12:35:30 Czytaj oryginał (ang.)
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-02-14 15:06:14 Czytaj oryginał (ang.)
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-02-14 12:36:13 Czytaj oryginał (ang.)
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. benzinga.com 2025-02-12 18:41:39 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update THB335 Phase 1 data support advancement into Phase 2 clinical trial in  chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to  maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at  8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers. globenewswire.com 2025-02-11 09:00:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m. globenewswire.com 2024-11-25 18:00:00 Czytaj oryginał (ang.)
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-11-11 13:00:35 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: globenewswire.com 2024-11-07 18:00:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Third Quarter 2024 Financial Results THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million  as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. globenewswire.com 2024-11-07 10:10:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: globenewswire.com 2024-09-10 20:00:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences: globenewswire.com 2024-08-26 20:00:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million  as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. “We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and now expect to report clinical results during the first quarter of 2025,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. globenewswire.com 2024-08-08 12:05:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. globenewswire.com 2024-05-28 20:05:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway,  with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D. globenewswire.com 2024-05-15 12:05:00 Czytaj oryginał (ang.)
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. globenewswire.com 2024-03-28 10:30:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. globenewswire.com 2024-03-26 10:05:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. globenewswire.com 2024-02-26 18:00:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD) NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders.  The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions. prnewswire.com 2024-02-22 13:08:00 Czytaj oryginał (ang.)
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy globenewswire.com 2024-01-04 10:00:00 Czytaj oryginał (ang.)
Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2023-12-29 15:32:16 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD) NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders.  The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions. prnewswire.com 2023-11-09 11:35:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Third Quarter 2023 Financial Results On track to file a U.S. Investigational New Drug (IND) application for THB335 and  initiate clinical studies in 1H'24 globenewswire.com 2023-11-09 10:30:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Leadership Changes SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company's Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors. globenewswire.com 2023-10-31 10:30:00 Czytaj oryginał (ang.)
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET. globenewswire.com 2023-08-31 12:30:00 Czytaj oryginał (ang.)
Third Harmonic Bio Announces Second Quarter 2023 Financial Results Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile globenewswire.com 2023-08-10 12:10:00 Czytaj oryginał (ang.)